Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Tingting Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Objectives
Ceftazidime–avibactam is effective against resistant Gram-negative bacteria but associated with a risk of acute kidney injury (AKI), with incidence rates ranging from 13.3% to 33.0%. This study developed a population pharmacokinetic (PopPK) model for ceftazidime–avibactam in critically ill Chinese adults, identified AKI risk factors using a time-to-event (TTE) model, and optimized dosing.
Methods
The PopPK model was developed using non-linear mixed-effects modelling (31 patients; 104 samples) and validated with 59 samples (32 patients). A TTE model identified AKI risk factors, and Monte Carlo simulations optimized dosing strategies based on these risks.
Results
Both ceftazidime and avibactam were best described by a one-compartment model. Creatinine clearance (CrCL) affected clearance of both, while avibactam clearance decreased with increasing C-reactive protein. AKI patients had higher exposure. The TTE analysis identified ceftazidime AUCss,24 h and mechanical ventilation (MV) as risk factors for AKI. Simulations supported a dual-objective optimization (efficacy, AUCss,24 h ≥ 784 μg·h/mL; safety, MV ≤ 1200 μg·h/mL, non-MV ≤ 2000 μg·h/mL) and renal function-stratified dosing recommendations [CrCL > 80 mL/min, 2.5 g q8h for MV/non-MV; CrCL 50–80, 1.25 g q8h for MV/non-MV; CrCL 30–50, 0.94 g q12h (MV) versus 1.25 g q8h (non-MV); CrCL 15–30, 0.94 g q24h (MV) versus 0.94 g q12h/q24h (non-MV); CrCL 6–15, 0.94 g q48h (MV) versus 0.94 g q24h/q48h (non-MV)].
Conclusions
The PopPK model for ceftazidime–avibactam was developed for critically ill Chinese adults. TTE analysis identified ceftazidime AUCss,24 h and MV as AKI risk factors. Renal function-guided dosing optimizes efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, China.
- Department of Intensive Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Qi Pei
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Wu, T., Ding, Q., Huang, S., Zhang, S., Yang, R., Qin, Y., Liu, J., & Pei, Q. (2025). Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf275
Vancouver
Wu T, Ding Q, Huang S, Zhang S, Yang R, Qin Y, et al. Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf275
BibTeX
@article{Wu2025,
author = {Wu, Tingting and Ding, Qin and Huang, Shuqi and Zhang, Shengnan and Yang, Ruwei and Qin, Yuanfang and Liu, Jingjing and Pei, Qi},
title = {Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf275}
}
EUVIMED